How to Safely Convert Opioids in the Clinical Setting

Article

Clinical pharmacist gives step-by-step demonstration of how to convert a patient from hydromorphone to extended-release morphine.

Karen Shapiro, PharmD, BCPS, discusses how to safely convert opioids in the clinical setting. By way of example, she discusses the case of a hospice patient who has been receiving 12 mg/d of IV hydromorphone but who now is to be converted to morphine extended-release Q12. In this example, the hospice policy is to reduce the new dose by 50% and to use 5-15% of the total daily dose for breakthrough pain. Topics discussed include the justification for reducing the new opioid dose and the need for breakthrough pain medication. Shapiro also cautions viewers that this conversion method does not work with fentanyl or methadone, as those medications “do not use straight-forward conversions.”

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
© 2024 MJH Life Sciences

All rights reserved.